News

The federal government and states will face a number of challenges upon establishing and operating federally facilitated health insurance exchanges.

Utah seeks hybrid exchange

Utah governor hopes to gain federal certification for the state's insurance exchange, which would ideally use a hybrid exchange model.

Although generally satisfied with global cancer research progress, the public believes it takes too long for new cancer drugs to reach patients.

FDA has approved pomalidomide (Pomalyst, Celgene) to treat patients who have received at least 2 prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Despite availability of many therapies indicated for bowel disorders, there is still an unmet need and heterogeneity among these patients, necessitating availability of a wide variety of therapeutics. Awareness of potential new products, their key benefits, and where they may fit into the treatment paradigm will be important when making decisions impacting patients and physicians, according to new analysis.

The development and implementation of evidence-based appropriateness criteria may help reduce costs associated with an increase in elective procedures.

In partnership with the Mayo Clinic, a UnitedHealthcare unit is putting data to work in a new facility to drive improved outcomes